GLP-1 Agonists in ADHD: Emerging Research into Neuropsychiatric Applications
Researchers are investigating whether GLP-1 receptor agonists like semaglutide could mitigate symptoms of ADHD by modulating dopamine pathways in the brain. While primarily used for diabetes and obesity, anecdotal evidence and early-stage studies suggest a potential role for these blockbuster drugs in treating executive dysfunction and impulsivity.